RLMD — Relmada Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $297.73m
- $283.85m
Annual cashflow statement for Relmada Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -59.5 | -126 | -157 | -98.8 | -80 |
| Depreciation | |||||
| Non-Cash Items | 20.8 | 41.7 | 42.6 | 44.1 | 29.8 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 10.8 | -7.86 | 10.6 | 3.08 | -1.58 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -27.8 | -91.9 | -104 | -51.7 | -51.8 |
| Other Investing Cash Flow Items | -34.4 | -54.1 | 19.7 | 50.5 | 51.6 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -34.4 | -54.1 | 19.7 | 50.5 | 51.6 |
| Financing Cash Flow Items | — | — | 0.374 | -0.098 | -0.287 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 28.5 | 188 | 45 | -0.098 | -0.04 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -33.8 | 41.9 | -39 | -1.3 | -0.235 |